Endocrinology Unit, Pediatric University Department, Bambino Gesù Children's Hospital, Research Institute, L.Go S.Onofrio, 4-00168, Rome, Italy.
Autoimmune Endocrine Diseases Unit, Bambino Gesù Children's Hospital, Research Institute, L.Go S.Onofrio, 4-00168, Rome, Italy.
J Endocrinol Invest. 2018 Jun;41(6):739-742. doi: 10.1007/s40618-017-0781-0. Epub 2017 Nov 3.
Obesity, insulin resistance, and puberty seem to influence and been inversely associated with 25-hydroxy vitamin D (25OHD) levels. To our knowledge, a study on 25OHD in children and adolescents with Prader-Willi syndrome (PWS), a genetic form of obesity, is not yet available.
To analyze the 25OHD values in pediatric PWS subjects in comparison with a control group (CNT), highlighting the possible correlations with IR, BMD, body composition, pubertal stage, and GH therapy (GHT).
Auxological and laboratory parameters, HOMA-IR, Vitamin D status, and bone density and body composition by DEXA scan were analyzed in 52 PWS and 110 controls (CNT), gender-, age-, and BMI-SD matched. None of them was on calcium or vitamin D. 20 PWS were on growth hormone (GH) therapy and 32 were previously treated.
Altogether, PWS had similar values of 25OHD compared to CNT.16 PWS (30.7%) and 27 CNT (24.5%) had low 25OHD levels (< 20 ng/ml) (p = NS). 25OHD of PWS on GHT were comparable to those previously treated. In both groups, univariate analysis showed a negative correlation between 25OHD and fat mass% (FM%). GH therapy and pubertal stage were positively correlated with bone parameters analyzed by DXA. Multivariate regression confirmed only FM% as negative predictor of 25HOD in PWS patients, as previously described. GHT does not seem to influence 25OHD in PWS.
Our data showed that PWS had similar values of 25OHD compared to CNT. As already described, FM seems to be the only parameter influencing 25OHD levels. Finally, GHT does not seem to influence 25OHD metabolism in PWS.
肥胖、胰岛素抵抗和青春期似乎会影响 25-羟维生素 D（25OHD）水平，并与 25OHD 水平呈负相关。据我们所知，目前尚无关于普拉德-威利综合征（PWS）患儿和青少年 25OHD 的研究，PWS 是一种遗传性肥胖症。
分析儿科 PWS 患者的 25OHD 值，并与对照组（CNT）进行比较，重点分析其与 IR、BMD、身体成分、青春期和生长激素治疗（GHT）的相关性。
对 52 例 PWS 和 110 例对照组（CNT）的生长发育和实验室参数、HOMA-IR、维生素 D 状况以及骨密度和身体成分进行分析，两组按性别、年龄和 BMI-SD 匹配。两组均未接受钙或维生素 D 治疗。20 例 PWS 接受生长激素（GH）治疗，32 例曾接受治疗。
总体而言，PWS 的 25OHD 值与 CNT 相似。16 例 PWS（30.7%）和 27 例 CNT（24.5%）的 25OHD 水平较低（<20ng/ml）（p=NS）。正在接受 GHT 的 PWS 患者的 25OHD 与之前接受治疗的患者相当。在两组中，单因素分析显示 25OHD 与脂肪量%（FM%）呈负相关。GH 治疗和青春期与 DXA 分析的骨参数呈正相关。多元回归仅证实 FM%是 PWS 患者 25HOD 的负预测因子，与之前的描述一致。GHT 似乎不会影响 PWS 患者的 25OHD。
我们的数据显示，PWS 的 25OHD 值与 CNT 相似。正如已经描述的，FM 似乎是唯一影响 25OHD 水平的参数。最后，GHT 似乎不会影响 PWS 患者的 25OHD 代谢。
